Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
123 hedge funds and large institutions have $399M invested in Keryx Biopharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 12 closing their positions.
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
12% more capital invested
Capital invested by funds: $355M → $399M (+$43.3M)
6% more funds holding
Funds holding: 116 → 123 (+7)
0.97% more ownership
Funds ownership: 63.23% → 64.2% (+0.97%)
5% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 38
30% less call options, than puts
Call options by funds: $3.06M | Put options by funds: $4.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$7.06M |
| 2 |
Millennium Management
New York
|
+$3.28M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.92M |
| 4 |
Morgan Stanley
New York
|
+$1.65M |
| 5 |
Bank of New York Mellon
New York
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.82M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.63M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.54M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
-$2.68M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.66M |
KERX Hedge Fund Activity: Q4 2016 in Review
123 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2016, worth a combined $399M — up 12% from $355M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KERX positions and 12 closed out — a net gain of 7 holders — while 36 added to existing stakes and 38 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $7.06M. The largest seller was Fidelity Investments, cutting an estimated $3.82M.
- 123 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2016, up from 116 in Q3 2016.
- Funds reported $399M of Keryx Biopharmaceuticals Inc stock for Q4 2016, up 12% quarter-over-quarter.
- 19 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2016 and 12 closed out, a net change of +7 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q4 2016 was Deerfield Management, an estimated $7.06M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q4 2016 was Fidelity Investments, an estimated $3.82M sold.
Based on aggregated 13F filings for Q4 2016.